496 related articles for article (PubMed ID: 14979058)
21. The role of cytokines in the pathogenesis of rheumatoid arthritis.
Feldmann M; Maini RN
Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():3-7. PubMed ID: 10646481
[TBL] [Abstract][Full Text] [Related]
22. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis.
Glossop JR; Dawes PT; Nixon NB; Mattey DL
Arthritis Res Ther; 2005; 7(6):R1227-34. PubMed ID: 16277675
[TBL] [Abstract][Full Text] [Related]
23. Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor alpha.
Edwards CK; Bendele AM; Reznikov LI; Fantuzzi G; Chlipala ES; Li L; Moldawer LL; Mountz JD; Li YY; Dinarello CA
Arthritis Rheum; 2006 Sep; 54(9):2872-85. PubMed ID: 16947419
[TBL] [Abstract][Full Text] [Related]
24. Effects of pro- and anti-inflammatory cytokines and nitric oxide donors on hyaluronic acid synthesis by synovial cells from patients with rheumatoid arthritis.
Chenevier-Gobeaux C; Morin-Robinet S; Lemarechal H; Poiraudeau S; Ekindjian JC; Borderie D
Clin Sci (Lond); 2004 Sep; 107(3):291-6. PubMed ID: 15149282
[TBL] [Abstract][Full Text] [Related]
25. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?
Feldmann M; Brennan FM; Paleolog E; Cope A; Taylor P; Williams R; Woody J; Maini RN
Novartis Found Symp; 2004; 256():53-69; discussion 69-73, 106-11, 266-9. PubMed ID: 15027483
[TBL] [Abstract][Full Text] [Related]
26. Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes.
Khoury M; Escriou V; Courties G; Galy A; Yao R; Largeau C; Scherman D; Jorgensen C; Apparailly F
Arthritis Rheum; 2008 Aug; 58(8):2356-67. PubMed ID: 18668557
[TBL] [Abstract][Full Text] [Related]
27. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition.
Butler DM; Malfait AM; Mason LJ; Warden PJ; Kollias G; Maini RN; Feldmann M; Brennan FM
J Immunol; 1997 Sep; 159(6):2867-76. PubMed ID: 9300710
[TBL] [Abstract][Full Text] [Related]
28. [The effect of the type II collagen protein from Zaocys on cytokines production by synoviocytes in rats with adjuvant arthritis].
Pang J; Li J; Wu XH; Wu HY
Zhong Yao Cai; 2009 Apr; 32(4):556-60. PubMed ID: 19645241
[TBL] [Abstract][Full Text] [Related]
29. [Interleukins network in rheumatoid arthritis pathophysiology: beyond proinflammatory cytokines].
Sánchez-Ramón S; López-Longo FJ; Carreño L
Reumatol Clin; 2011 Mar; 6S3():S20-4. PubMed ID: 21794767
[TBL] [Abstract][Full Text] [Related]
30. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.
Zwerina J; Hayer S; Redlich K; Bobacz K; Kollias G; Smolen JS; Schett G
Arthritis Rheum; 2006 Feb; 54(2):463-72. PubMed ID: 16447221
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-1, tumor necrosis factor and their specific inhibitors.
Dayer JM; Burger D
Eur Cytokine Netw; 1994; 5(6):563-71. PubMed ID: 7727689
[TBL] [Abstract][Full Text] [Related]
32. Interleukin 1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis?
Dayer JM
J Rheumatol Suppl; 2002 Sep; 65():10-5. PubMed ID: 12236616
[TBL] [Abstract][Full Text] [Related]
33. Effector function of type II collagen-stimulated T cells from rheumatoid arthritis patients: cross-talk between T cells and synovial fibroblasts.
Cho ML; Yoon CH; Hwang SY; Park MK; Min SY; Lee SH; Park SH; Kim HY
Arthritis Rheum; 2004 Mar; 50(3):776-84. PubMed ID: 15022319
[TBL] [Abstract][Full Text] [Related]
34. [Present and future therapeutic strategies in rheumatoid arthritis].
Schacht E
Z Rheumatol; 1993; 52(6):365-82. PubMed ID: 8147131
[TBL] [Abstract][Full Text] [Related]
35. Tumour necrosis factor-alpha as a new therapeutic target for rheumatoid arthritis: an update.
Giasuddin AS; Hoque ME; Ahmed ZU
Bangladesh Med Res Counc Bull; 2005 Dec; 31(3):88-94. PubMed ID: 17549869
[TBL] [Abstract][Full Text] [Related]
36. [Cytokines, growth factors and inflammation].
Pujol JP
Rev Rhum Mal Osteoartic; 1988 Apr; 55(6):430-4. PubMed ID: 3134688
[TBL] [Abstract][Full Text] [Related]
37. Joint inflammation and cytokine inhibition in rheumatoid arthritis.
Christodoulou C; Choy EH
Clin Exp Med; 2006 Mar; 6(1):13-9. PubMed ID: 16550339
[TBL] [Abstract][Full Text] [Related]
38. Nonsteroidal anti-inflammatory drugs increase TNF production in rheumatoid synovial membrane cultures and whole blood.
Page TH; Turner JJ; Brown AC; Timms EM; Inglis JJ; Brennan FM; Foxwell BM; Ray KP; Feldmann M
J Immunol; 2010 Sep; 185(6):3694-701. PubMed ID: 20713883
[TBL] [Abstract][Full Text] [Related]
39. [Role of cytokines and growth factors in joint destruction processes].
Alsalameh S; Jerez R; Bujía J; Haeupl T; Kalden JR; Burmester GR
Rev Med Chil; 1992 Dec; 120(12):1400-10. PubMed ID: 1343382
[TBL] [Abstract][Full Text] [Related]
40. Pathogenesis of rheumatoid arthritis: targeting cytokines.
Zwerina J; Redlich K; Schett G; Smolen JS
Ann N Y Acad Sci; 2005 Jun; 1051():716-29. PubMed ID: 16127012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
